Starpharma Holdings Limited SPHRY
2.97 USD -0.24 (-7.48%)
At closeNov 10, 2026, 4:00 PM EST
2.82 Day range 2.82
2.20 52-week range 5.98
- YTD
- +22.22%
- 1 year
- +29.13%
News
defenseworld.net Starpharma (OTCMKTS:SPHRY) Stock Price Down 13.7% – Time to Sell? Starpharma Holdings Ltd. (OTCMKTS:SPHRY - Get Free Report) dropped 13.7% during mid-day trading on Friday. The company traded as low as $5.05 and last traded at $5.05. 1,020 shares traded hands…
prnewswire.com US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments MELBOURNE, Australia, Sept. 15, 2021 /PRNewswire/ -- DEP® cabazitaxel is a proprietary nanoparticle version of leading prostate cancer drug cabazitaxel (Jevtana®), which had global sales of US$536…
seekingalpha.com Stopping Infection: A Missing Link In The Delta Puzzle? Unloved Investment Opportunity In Starpharma The delta variant of SARS-CoV-2 is changing the rules of engagement because it is highly infectious and it gets passed on rapidly.
seekingalpha.com Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack
seekingalpha.com Starpharma Up With News, Down With None; Timing Entry Makes Sense Starpharma Up With News, Down With None; Timing Entry Makes Sense
prnewswire.com Starpharma signs DEP® ADC Research Agreement with MSD MELBOURNE, Australia, Feb. 11, 2021 /PRNewswire/ -- Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that is has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc.,…
seekingalpha.com Starpharma Viraleze: COVID-19 Nasal Spray Development Viraleze antiviral could be effective against SAS-CoV-2 and RSV. Boston Consulting Group is involved in positioning and marketing this preventative/early stage infection product. Viraleze has a…
benzinga.com Stocks That Hit 52-Week Lows On Tuesday